These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 39046116)

  • 1. Risk of age-related macular degeneration in men receiving 5α-reductase inhibitors: a population-based cohort study.
    Su YC; Shen CY; Shao SC; Lai CC; Hsu SM; Lee CN; Liu CJ; Hung JH; Lai EC
    Age Ageing; 2024 Jul; 53(7):. PubMed ID: 39046116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence of type 2 diabetes mellitus in men receiving steroid 5α-reductase inhibitors: population based cohort study.
    Wei L; Lai EC; Kao-Yang YH; Walker BR; MacDonald TM; Andrew R
    BMJ; 2019 Apr; 365():l1204. PubMed ID: 30971393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia.
    Duan Y; Grady JJ; Albertsen PC; Helen Wu Z
    Pharmacoepidemiol Drug Saf; 2018 Mar; 27(3):340-348. PubMed ID: 29316005
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 5α-Reductase inhibitors increase acute coronary syndrome risk in patients with benign prostate hyperplasia.
    Chou CH; Lin CL; Lin MC; Sung FC; Kao CH
    J Endocrinol Invest; 2015 Jul; 38(7):799-805. PubMed ID: 25778849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparing Clinical and Economic Outcomes Associated with Early Initiation of Combination Therapy of an Alpha Blocker and Dutasteride or Finasteride in Men with Benign Prostatic Hyperplasia in the United States.
    DerSarkissian M; Xiao Y; Duh MS; Lefebvre P; Swensen AR; Bell CF
    J Manag Care Spec Pharm; 2016 Oct; 22(10):1204-14. PubMed ID: 27668569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sexual dysfunction in subjects treated with inhibitors of 5α-reductase for benign prostatic hyperplasia: a comprehensive review and meta-analysis.
    Corona G; Tirabassi G; Santi D; Maseroli E; Gacci M; Dicuio M; Sforza A; Mannucci E; Maggi M
    Andrology; 2017 Jul; 5(4):671-678. PubMed ID: 28453908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A population-based nested case-control study: the use of 5-alpha-reductase inhibitors and the increased risk of osteoporosis diagnosis in patients with benign prostate hyperplasia.
    Lin WL; Hsieh YW; Lin CL; Sung FC; Wu CH; Kao CH
    Clin Endocrinol (Oxf); 2015 Apr; 82(4):503-8. PubMed ID: 25158777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rates of prostate surgery and acute urinary retention for benign prostatic hyperplasia in men treated with dutasteride or finasteride.
    Kuiper JG; Bezemer ID; Driessen MT; Vasylyev A; Roehrborn CG; Penning-van Beest FJ; Herings RM
    BMC Urol; 2016 Aug; 16(1):53. PubMed ID: 27580700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A population-based nested case-control study in taiwan: use of 5α-reductase inhibitors did not decrease prostate cancer risk in patients with benign prostate hyperplasia.
    Liang JA; Sun LM; Lin MC; Chang SN; Sung FC; Muo CH; Kao CH
    Oncologist; 2012; 17(7):986-91. PubMed ID: 22723508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Free combination of dutasteride plus tamsulosin for the treatment of benign prostatic hyperplasia in South Korea: analysis of drug utilization and adverse events using the National Health Insurance Review and Assessment Service database.
    Lulic Z; Son H; Yoo SB; Cunnington M; Kapse P; Miller D; Cortes V; Park S; Bhak RH; Duh MS
    BMC Urol; 2021 Dec; 21(1):178. PubMed ID: 34933674
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of 5α-Reductase Inhibitors on Sexual Function: A Meta-Analysis and Systematic Review of Randomized Controlled Trials.
    Liu L; Zhao S; Li F; Li E; Kang R; Luo L; Luo J; Wan S; Zhao Z
    J Sex Med; 2016 Sep; 13(9):1297-1310. PubMed ID: 27475241
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of 5α-Reductase Inhibitors With Dementia, Depression, and Suicide.
    Garcia-Argibay M; Hiyoshi A; Fall K; Montgomery S
    JAMA Netw Open; 2022 Dec; 5(12):e2248135. PubMed ID: 36547981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 5α-Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men With Prostate Cancer.
    Azoulay L; Eberg M; Benayoun S; Pollak M
    JAMA Oncol; 2015 Jun; 1(3):314-20. PubMed ID: 26181177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association between
    Madersbacher S; Rieken M; Reuber K; Kostev K
    Postgrad Med; 2023 Mar; 135(2):149-154. PubMed ID: 36408978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.
    Roehrborn CG; Barkin J; Siami P; Tubaro A; Wilson TH; Morrill BB; Gagnier RP
    BJU Int; 2011 Mar; 107(6):946-54. PubMed ID: 21332630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology.
    Bird ST; Delaney JA; Brophy JM; Etminan M; Skeldon SC; Hartzema AG
    BMJ; 2013 Nov; 347():f6320. PubMed ID: 24192967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of combination therapy with tamsulosin, dutasteride and imidafenacin for the management of overactive bladder symptoms associated with benign prostatic hyperplasia: A multicenter, randomized, open-label, controlled trial (DIrecT Study).
    Yamanishi T; Asakura H; Seki N; Tokunaga S
    Int J Urol; 2017 Jul; 24(7):525-531. PubMed ID: 28466585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Cardiovascular Safety of Dutasteride.
    Skeldon SC; Macdonald EM; Law MR; Huang A; Paterson JM; Mamdani MM; Juurlink D
    J Urol; 2017 May; 197(5):1309-1314. PubMed ID: 27866006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of dutasteride and finasteride on BPH-related hospitalization, surgery and prostate cancer diagnosis: a record-linkage analysis.
    Cindolo L; Fanizza C; Romero M; Pirozzi L; Autorino R; Berardinelli F; Schips L
    World J Urol; 2013 Jun; 31(3):665-71. PubMed ID: 23239103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia.
    Zhou Z; Cui Y; Wu J; Ding R; Cai T; Gao Z
    BMC Urol; 2019 Mar; 19(1):17. PubMed ID: 30871552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.